Law Firm Probes Beta Bionics’ 36% Patient Growth Miss and 35% Stock Drop
BBNX•BBNX•BBNX•BBNX•Johnson Fistel PLLP is investigating whether Beta Bionics or its executives violated federal securities laws after reporting preliminary fourth-quarter 2025 results. The company reported 5,581 new patient starts, a 36% year-over-year increase but down from 68% last quarter, triggering a stock price drop of over 35%.
Johnson Fistel PLLP has opened a federal securities investigation into Beta Bionics and certain officers to determine whether investors can recover losses stemming from potentially misleading disclosures.
On January 8, 2026, Beta Bionics disclosed preliminary, unaudited fourth-quarter results showing 5,581 new patient starts, reflecting 36% year-over-year growth versus 68% growth in the prior quarter, falling short of analyst expectations.
Following the disclosure, Beta Bionics’ stock plunged more than 35% on January 9, 2026, prompting investors to seek potential claims for recovery under federal securities laws.
